Drug intelligence / Profile preview

RiaGev

Development stage: Unknown
Lead developer: Bioenergy Life Science
Modality: Small Molecules
Administration: Oral

Overview

RiaGev is a proprietary combination of D-ribose and nicotinamide developed by Bioenergy Life Science. It is designed to enhance the body's production of nicotinamide adenine dinucleotide (NAD+) by directly entering the salvage pathway. Clinical studies in healthy middle-aged adults have demonstrated that supplementation can increase the NAD+ metabolome, particularly NADP+ levels, and may improve insulin sensitivity and glucose tolerance. Although evaluated in clinical trials for metabolic health benefits, it is primarily marketed as a dietary supplement rather than an approved pharmaceutical drug.

Brand names: RiaGev
Other names: D-ribose + nicotinamidenicotinamide + D-ribose

Targets

NAD (Nicotinamide adenine dinucleotide)

Beyond the preview

Go deeper on RiaGev.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RiaGev.

Explore the full profile